LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

Search

Cerus Corp

Closed

SectorHealthcare

1.4 6.06

Overview

Share price change

24h

Current

Min

1.3

Max

1.4

Key metrics

By Trading Economics

Income

-5.2M

-7.7M

Sales

-7.6M

43M

EPS

-0.04

Profit margin

-17.85

Employees

614

EBITDA

-5.8M

-5.9M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+253.79% upside

Dividends

By Dow Jones

Next Earnings

31 lip 2025

Market Stats

By TradingEconomics

Market Cap

21M

281M

Previous open

-4.66

Previous close

1.4

News Sentiment

By Acuity

88%

12%

363 / 381 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Cerus Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 cze 2025, 22:33 UTC

Acquisitions, Mergers, Takeovers

KKR to Acquire Australian Power Provider Zenith Energy

16 cze 2025, 21:55 UTC

Major Market Movers

Geospace Technologies Shares Up on Petrobras Pact

16 cze 2025, 17:04 UTC

Major Market Movers

Roku Shares Climb on Advertising Deal with Amazon

16 cze 2025, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 cze 2025, 23:51 UTC

Market Talk

Nikkei May Trade Range Bound Amid Israel-Iran Conflict -- Market Talk

16 cze 2025, 23:41 UTC

Market Talk

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

16 cze 2025, 23:10 UTC

Market Talk
Acquisitions, Mergers, Takeovers

XRG Has 'Viable Path' to Approval of Santos Takeover -- Market Talk

16 cze 2025, 23:02 UTC

Market Talk

Auckland Airport Unlikely to Hit Target for International Passengers -- Market Talk

16 cze 2025, 22:32 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Santos Unlikely to Attract Rival Bidder to XRG -- Market Talk

16 cze 2025, 22:03 UTC

Acquisitions, Mergers, Takeovers

KKR & Co. to Buy Zenith Energy From Consortium Including Pacific Equity Partners, OPSEU Pension Trust, Foresight Group >KKR

16 cze 2025, 22:00 UTC

Acquisitions, Mergers, Takeovers

KKR Acquires Leading Australian Independent Power Producer Zenith Energy >KKR

16 cze 2025, 21:56 UTC

Earnings

Lennar Has an Earnings Miss. The Stock Slips. -- Barrons.com

16 cze 2025, 21:10 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi in Talks to Sign $8 Billion Deal With Gas Producer Aethon -- WSJ

16 cze 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 cze 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

16 cze 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 cze 2025, 20:49 UTC

Market Talk

Fitch Revises Canadian Provinces Fiscal Outlook to 'Deteriorating' -- Market Talk

16 cze 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Update: EchoStar Stock Surges. It's Short Covering and President Trump. -- Barrons.com

16 cze 2025, 20:13 UTC

Market Talk

Natural Gas Gains on Warmer Outlook -- Market Talk

16 cze 2025, 19:58 UTC

Acquisitions, Mergers, Takeovers

OpenAI and Microsoft Tensions Are Reaching a Boiling Point -- WSJ

16 cze 2025, 19:13 UTC

Market Talk

Middle-East Conflict May Not Push Up Oil Long Term -- Market Talk

16 cze 2025, 19:09 UTC

Market Talk

Amazon-Roku Deal Shows Competition for Streaming Ad Space -- Market Talk

16 cze 2025, 18:43 UTC

Market Talk

May Could Mark Nascent Recovery in Canada Housing Market -- Market Talk

16 cze 2025, 18:36 UTC

Market Talk

Soybeans May Get Boost from Renewable Fuel Obligations -- Market Talk

16 cze 2025, 18:29 UTC

Market Talk

Global Equities Roundup: Market Talk

16 cze 2025, 18:29 UTC

Market Talk

Shopify Appears More Resilient Than Feared -- Market Talk

16 cze 2025, 18:22 UTC

Market Talk

Citi Forecasts Downturn in Gold Futures -- Market Talk

16 cze 2025, 16:42 UTC

Market Talk

Homebuyers' Downpayments Are Shrinking For First Time in 2 Years -- Market Talk

16 cze 2025, 16:37 UTC

Market Talk

Big, Beautiful Bill Might Not Mean Big Growth -- Market Talk

16 cze 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Peer Comparison

Price change

Cerus Corp Forecast

Price Target

By TipRanks

253.79% upside

12 Months Forecast

Average 4.67 USD  253.79%

High 5 USD

Low 4 USD

Based on 4 Wall Street analysts offering 12 month price targets forCerus Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

3

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

1.3 / 1.36Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

363 / 381 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.